By Maxx Chatsko Dice Therapeutics shares leaped on positive data for its lead drug candidate. What comes next? Investors for months were anxiously awaiting the first-ever clinical data from Dice Therapeutics (DICE) . The results didn’t disappoint them. The company’s lead drug candidate, DC-806, aced a small phase 1 study focused on psoriasis. No development-derailing side effects for any dose levels tested occurred. And although the clinical trial wasn’t designed to evaluate efficacy, an exploratory endpoint suggests that the asset could be competitive with other orally administered autoimmune…